Top Markets
#1 Islamic Coin Islamic Coin +151.22%
#2 Akedo Akedo +76.34%
#3 Velvet Velvet +52.62%
#4 Glidr Glidr +51.75%
#5 DOVU DOVU +47.94%
#6 Black Phoenix Black Phoenix +33.93%
#7 Cross Cross +31.13%
#8 Cap Cap +21.55%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.55%
#10 DoubleZero DoubleZero +14.82%
Coin of the day
Islamic Coin Islamic Coin
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Classificação em ações #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Preço da ação
$0.11725176
Última sincronização: 2025-07-14
Valor de mercado
$481.50K
Variação (1 dia)
-0.20%
Variação (1 ano)
0.00%
País
FR
Negociar PHAXIAM Therapeutics S.A. (PHXM)

Categoria

Healthcare
Receita da PHAXIAM Therapeutics S.A. (PHXM)
Receita em Jun 2024 TTM: $2.30M
De acordo com os últimos relatórios financeiros da PHAXIAM Therapeutics S.A., a receita atual da empresa (TTM) é $2.30M. Em 2022, a empresa obteve uma receita de $7.13M um aumento em relação a a receita do ano 2021, que foi de $4.75M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da PHAXIAM Therapeutics S.A. de 2016 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $2.30M 56.82%
2023 $1.47M -79.44%
2022 $7.13M 50.00%
2021 $4.75M 4.97%
2020 $4.53M -23.61%
2019 $5.93M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 549,098.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 261,845.69%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 439,752.28%
BE